m7G(5')ppp(5')A RNA Cap Structure Analog, New England Biolabs

About this item

The 5´terminal m7G cap present on most eukaryotic mRNAs promotes translation in vitro at the initiation level.

For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation, and a decrease in the formation of the initiation complex of mRNAs for protein synthesis. Certain prokaryotic mRNAs containing a 5´ terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system. Also a cap requirement has been observed for splicing eukaryotic substrate RNAs. A method using E. coli RNA Polymerase primed with m7G(5´)ppp(5´)G or m7G(5´)ppp(5´)A for an efficient in vitro synthesis of capped RNAs has been developed by Contreas. Larger amounts of capped RNAs are produced by transcription systems using SP6 RNA polymerase primed with m7G(5´)ppp(5´)G.

Restricted Products: To process your orders without delay, please provide the required business documentation to purchase this product.

To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:

• State issued document with your organization's Federal Tax ID Number
• State issued document with your organization's Resale Tax ID Number
• City or County issued Business License
• State Department of Health Services License
• Any other ID issued by the State that includes the business name & address

* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.